# Lyell Immunopharma (LYEL) — Earnings

LYEL · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/lyel/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$2.89 |
| EPS estimate | −$3.52 |
| EPS surprise | +17.90% |
| Revenue surprise | +100.00% |
| Revenue | $8,000.00 |
| Revenue estimate | $4,000.00 |
| Reported | Aug 12, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1806952/000180695225000008/lyel-20250630.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 12, 2025 | −$3.52 | −$2.89 | 17.90% | $4,000.00 | $8,000.00 |
| Q1 2025 | May 13, 2025 | −$3.60 | −$1.86 | 48.33% | — | $7,000.00 |
| Q4 2024 | Mar 11, 2025 | −$3.40 | −$8.90 | -161.76% | — | $11,000.00 |
| Q3 2024 | Nov 7, 2024 | −$3.90 | −$3.40 | 12.82% | — | $34,000.00 |
| Q2 2024 | Aug 7, 2024 | −$3.95 | −$3.60 | 8.86% | $3,250.00 | $13,000.00 |
| Q1 2024 | May 6, 2024 | −$4.40 | −$4.79 | -8.78% | $1,000.00 | $3,000.00 |
| Q4 2023 | Feb 28, 2024 | −$4.60 | −$4.20 | 8.70% | $3,250.00 | $13,000.00 |
| Q3 2023 | Nov 7, 2023 | −$4.84 | −$4.00 | 17.36% | $6,250.00 | $25,000.00 |
| Q2 2023 | Aug 8, 2023 | −$5.25 | −$5.20 | 0.95% | $18,000.00 | $27,000.00 |
| Q1 2023 | May 4, 2023 | −$5.15 | −$3.60 | 30.10% | — | $65,000.00 |
| Q4 2022 | Feb 28, 2023 | −$4.55 | −$0.60 | 86.81% | $16.1M | $48.4M |
| Q3 2022 | Nov 8, 2022 | −$6.22 | −$5.60 | 9.99% | $1.8M | $2.8M |
| Q2 2022 | Aug 4, 2022 | −$4.38 | −$1.90 | 56.65% | $17.9M | $35.7M |
| Q1 2022 | May 10, 2022 | −$5.55 | −$5.54 | 0.23% | $776,500.00 | $553,000.00 |
| Q4 2021 | Mar 29, 2022 | −$5.41 | −$7.00 | -29.42% | $2.6M | $2.8M |
| Q3 2021 | Nov 12, 2021 | −$9.40 | −$3.54 | 62.32% | $2.9M | $2.8M |
| Q2 2021 | Aug 12, 2021 | −$7.50 | −$29.40 | -292.00% | $2.3M | $2.6M |

## Frequently Asked Questions

### When did Lyell Immunopharma (LYEL) last report earnings?

Lyell Immunopharma last reported on Aug 12, 2025, covering fiscal Q2 2025.

### Did LYEL beat earnings estimates?

Yes. Lyell Immunopharma reported EPS of −$2.89 for Q2 2025 against a −$3.52 estimate — a 17.90% beat.

### How much revenue did LYEL report last quarter?

Lyell Immunopharma reported $8,000.00 in revenue for Q2 2025, against a consensus estimate of $4,000.00.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).